QHSLAB INC (OTCQB:USAQ)

QHSLAB INC (OTCQB:USAQ) – announced it has entered into a strategic partnership with Town Total Compounding, a PCAB-accredited pharmacy specializing in sterile and non-sterile compounding to expand market opportunities.

“This collaboration will introduce QHSLab's Integrated Service Program (ISP) to over 200 primary care medical practices within Town Total’s network, aligning digital medicine assessments with personalized prescription therapies for GLP-1s, Hormone Replacement Therapy (HRT), Allergen Immunotherapy, Pain Management, and Dermatological treatments”.

A Non-Dilutive, Scalable Growth Strategy:

“This co-marketing initiative underscores both companies' commitment to expanding market reach without requiring additional capital investment. By integrating QHSLab’s digital health capabilities into Town Total’s established provider relationships, the partnership fosters organic business growth, enhances provider engagement, and drives better patient adherence and treatment outcomes.”

QHSLAB INC (OTCQB:USAQ) ($0.28; $3.1 M market cap) - announced record revenue growth and positive net income in preliminary Q4 and full year 2024 results:

• Revenue surged 98% year-over-year to $625,981, compared to $315,020 in Q4 2023, marking four consecutive quarters of year-over-year revenue growth, marking a milestone year for QHSLab.
• Operational efficiencies and strategic execution drive the first profitable year. 
• Net income for Q4 2024 of $40,838, a significant improvement from a net loss of $86,627 in Q4 2023.
• Revenue grew 51% year-over-year, reaching $2.1 million compared to $1.4 million for the full-year 2023.
• Gross margin improved to 63.7%, reflecting an enhanced product mix and increased operational efficiencies.
• The Company recorded net income of $69,188 for 2024, compared to a net loss of $468,362 in 2023, underscoring QHSLab’s strong financial momentum and commitment to profitable operations.

“These outstanding financial results reflect the continued execution of our strategic initiatives and the growing adoption of our digital medicine solutions,” said Troy Grogan, President and CEO of QHSLab. “We are thrilled to report 98% revenue growth compared to Q4 2023, despite the fourth quarter historically being a lower performing quarter for healthcare companies due to the seasonal impact of patient volume. This growth demonstrates the strength of our business model and the resilience of our operations. Our improved gross margin and profitability highlight the effectiveness of our operational efficiencies and commitment to achieving and sustaining profitability. As we increase the number of physicians using QHSLab, our financial performance should continue to improve.”

Audit status and future outlook:

“The Company is currently finalizing its independent year-end audit in preparation for filing its Annual Report on Form 10-K prior to the 2024 SEC reporting deadline. While these financial results remain unaudited and are subject to change, management is confident in the reported numbers and expects only minor adjustments, if any.

“We look forward to sharing our fully audited results in the coming weeks and remain committed to delivering strong financial performance and value to our shareholders,” added Troy Grogan. “With our continued expansion and operational efficiencies, we are excited about the future of QHSLab as we build on this momentum into 2025.”

In May 2024, Contributor Todd Schuh published an article on USAQ nearing an inflection point, which you can read here. 

We continue to monitor to see if the Company will take steps to eliminate convertible debt (when valuing the company investors should note the dilutive effect of the convertible debt of about 10 million shares, which would bring total shares to about 20 million).

QHSLab, Inc. is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians.